Lv72
4758 积分 2021-08-24 加入
Third generation EGFR TKIs: current data and future directions
3天前
已完结
Overcoming therapy resistance in EGFR-mutant lung cancer
3天前
已完结
Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy
3天前
已完结
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
3天前
已完结
Current Progress and Future Directions of Immunotherapy in Head and Neck Squamous Cell Carcinoma: A Narrative Review
10天前
已完结
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer
11天前
已完结
A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes
20天前
已完结
PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients
28天前
已完结
Immunotherapy in thymic epithelial tumors: an attractive dilemma
29天前
已完结
Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial
29天前
已完结
皖公网安备34019202002308
